Substance-P for Gastrointestinal Damage Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments lack effective solutions for preventing or treating gastrointestinal damage caused by radiation and chemotherapy, which can lead to severe side effects and tissue damage.

Innovation Solution

A composition containing Substance-P as an active ingredient, administered therapeutically to mammals, which prevents apoptosis and promotes regeneration of gastrointestinal cells, thereby reducing damage and accelerating recovery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If radiotherapy or chemotherapy is administered to treat cancer, then cancer cells are destroyed, but gastrointestinal damage occurs due to damage to normal cells

Engineering Contradiction:

Improvecancer treatment effectivenessVSAvoidgastrointestinal damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies Substance-P to convert the harmful effect of chemotherapy and radiotherapy on gastrointestinal cells into a beneficial effect. Substance-P binds to neurokinin-1 receptors on gastrointestinal epithelial cells, activating signaling pathways that prevent apoptosis and promote cell survival, thereby transforming the previously harmful radiation/chemotherapy exposure into a treatable condition with a specific therapeutic agent

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

Substance-P acts as an intermediary substance that mediates between the harmful treatment (radiotherapy/chemotherapy) and the gastrointestinal cells. It binds to neurokinin-1 receptors on the cell surface and transmits protective signals through intracellular pathways (PKC, MAPK/ERK, PI3K/Akt), serving as a chemical mediator that blocks the transmission of damage signals while allowing the cancer-killing effects of treatment to continue

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of manufacture

If conventional treatments are used for gastrointestinal damage, then standard care is provided, but effective prevention or treatment is lacking

Engineering Contradiction:

Improveavailability of treatmentVSAvoidtreatment effectiveness

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent changes the therapeutic parameter from conventional supportive care (antiemetics, fluid management) to a targeted biological agent (Substance-P) that specifically addresses the molecular mechanisms of gastrointestinal cell damage. This parameter change involves administering Substance-P at specific dosages (e.g., 1-100 μg/kg body weight) to achieve protective effects that were previously unavailable with conventional treatments

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS7846901B2Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P

Publication Date: 2010.12.07 UNIVERSITY INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY

AI summary

Disclosed herein are a composition for prevention or treatment of gastrointestinal damage comprising Substance-P as an active ingredient, a use of Substance-P for the preparation of a medicament for prevention or treatment of gastrointestinal damage, and a method for prevention or treatment of gastrointestinal damage comprising administering a therapeutically effective amount of Substance-P to a mammal.